Bitcoin steigt nach dem Halving wieder über 9‘000 Franken. Jetzt Bitcoin handeln! -w-
<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Strukturierte Produkte
>
16.05.2018 13:00:00

Bio-Path Holdings Reports First Quarter 2018 Financial Results

HOUSTON, May 16, 2018 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the first quarter ended March 31, 2018 and provided an update on recent corporate developments."Throughout the first quarter of 2018, we made major strides advancing our RNAi nanoparticle drugs for the treatment of a variety of cancers with limited treatment options. Specifically, we were delighted to publish and present data in support of our DNAbilize® technology in both peer-viewed journal articles and at key oncology medical meetings.  In particular, we were delighted with the interim results from our ongoing Phase 2 clinical trial of prexigebersen for the treatment of AML, which showed 47% of evaluable patients demonstrated some degree of response to prexigebersen in combination with LDAC, representing a significant advance for de-novo patients previously untreated for AML who are not otherwise eligible for standard or high-intensity chemotherapy regimens or who have elected a low intensity regimen," said Peter Nielsen, President and CEO of Bio-Path Holdings."Moving forward, we continue to leverage our DNAbilize® RNAi nanoparticle technology to develop treatments for other cancers with high unmet medical need. To that end, we have gathered a team of leading cancer and biotechnology experts to guide our current and future clinical programs. We remain committed to our mission of advancing novel treatments for oncology patients with limited treatment options and will continue to drive the advancement of Bio-Path's exciting drug candidates," continued Mr. Nielsen.                                                     Recent Corporate HighlightsReported interim results from Phase 2 study of prexigebersen in combination with LDAC for the treatment of AML. In April ...Full story available on Benzinga.com
Weiter zum vollständigen Artikel bei "Benzinga"

Analysen zu Bio-Path Holdings Inc Registered Shsmehr Analysen

Eintrag hinzufügen

Aktien Top Flop

Swisscom 499.80
1.42 %
Alcon 61.88
1.38 %
Nestle 103.86
0.99 %
Givaudan 3’447.00
0.50 %
SGS 2’255.00
0.31 %
ABB 18.89
-2.05 %
Adecco Group 45.62
-2.25 %
Roche Hldg G 332.70
-2.51 %
Swiss Re 65.12
-3.10 %
CS Group 8.77
-3.96 %
Wieso hinkt der SMI hinterher?

Finanzen.net News

pagehit